SCHEMBL1355584

SCHEMBL1355584

COc1ccc(-n2ncc3cnc(Nc4ccc(O)c(C=O)c4)nc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 4/20 0.57
TBK1 Q9UHD2 2/20 0.49
CDK4 P11802 2/20 0.45
CCND1 P24385 2/20 0.45
CCND2 P30279 2/20 0.45
CCND3 P30281 2/20 0.45
FLT3 P36888 9/20 0.43
AURKA O14965 1/20 0.43
DAPK3 O43293 1/20 0.43
JAK2 O60674 1/20 0.43
PAK4 O96013 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
IGF1R P08069 1/20 0.43
MET P08581 1/20 0.43
PDGFRB P09619 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1356019 0.86 EIF2AK4 (0.61) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1356682 0.86 EIF2AK4 (0.61) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1353781 0.85 EIF2AK4 (0.57) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1355858 0.84 EIF2AK4 (0.61) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1356007 0.82 EIF2AK4 (0.67) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1353618 0.81 EIF2AK4 (0.62) EIF2AK4TBK1FLT3AURKADAPK3
SCHEMBL1355821 0.81 EIF2AK4 (0.62) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1355771 0.81 EIF2AK4 (0.64) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1353635 0.79 EIF2AK4 (0.66) EIF2AK4TBK1FLT3FGFR1PTK2
SCHEMBL1355646 0.79 FLT3 (0.64) EIF2AK4TBK1CDK4CCND1CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885TBK1 1295/4885CDK4 101/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885TBK1 1295/4885CDK4 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.